Evotec SE (NASDAQ:EVO - Free Report) - Stock analysts at HC Wainwright reduced their FY2027 earnings per share estimates for shares of Evotec in a report issued on Monday, April 21st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $0.42 per share for the year, down from their previous estimate of $0.47. The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's FY2028 earnings at $0.57 EPS and FY2029 earnings at $0.70 EPS.
Separately, Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a research note on Thursday.
Check Out Our Latest Analysis on Evotec
Evotec Stock Performance
Shares of EVO traded up $0.01 during mid-day trading on Tuesday, hitting $4.22. 21,000 shares of the company's stock were exchanged, compared to its average volume of 132,271. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. Evotec has a fifty-two week low of $2.84 and a fifty-two week high of $5.68. The business's 50 day moving average is $3.64 and its two-hundred day moving average is $4.10.
Institutional Trading of Evotec
Several hedge funds have recently made changes to their positions in EVO. DCF Advisers LLC increased its stake in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after acquiring an additional 12,816 shares during the period. Lighthouse Investment Partners LLC acquired a new position in Evotec during the 4th quarter worth approximately $166,000. Bank of America Corp DE raised its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares in the last quarter. CSS LLC IL purchased a new position in shares of Evotec during the 4th quarter worth approximately $50,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Evotec in the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
